Top of page Skip navigation
  • REGISTRATION NOW OPEN

    Early Bird fees available until 25 August

  • SAVE THE DATE

    Join us in Cardiff on 29 and 30 November 2017

Speakers

Dr Caroline Barelle

Chief Executive Officer, Elasmogen

Caroline is CEO and co-founder of the next generation therapeutic biologics company, Elasmogen.  The company discovers and develops soloMERs which are novel drugs for the treatment of auto-immune inflammatory diseases and cancer.  Prior to setting up Elasmogen, Caroline was Head of Shark IgNAR Development in Pfizer and Wyeth where she was responsible for establishing robust platforms for the isolation of these binding domains and progressing pipeline candidates. 

 

Her first experience of developing biologics drugs was during her time with the antibody engineering spin-out company, Haptogen, where she was Programmes and Alliance manager.  Caroline obtained her PhD in biochemistry at the University of Aberdeen and an MBA (distinction) from Robert Gordon’s University, Business School. 

Simon Barnes

Commercial Director, High Speed Sustainable Manufacturing Institute

Simon is Commercial Director at HSSMI. He is responsible for HSSMI’s commercial services and product development.  He has a breadth of experience in developing successful and innovative membership organisations across a wide range of industry sectors.

Simon’s experience has included the automotive, marine, grocery and paper manufacturing sectors for both UK and international businesses. He has developed knowledge in understanding complex as well as immature supply chains and appreciating factors that contribute to both the success and failure of these.

Simon has a degree in International Studies from Cardiff University and a Post Graduate Diploma in Sustainable Business.

Dr Mark Bustard

Specialist, Medicines Manufacturing, KTN

Mark is responsible for defining and delivering the medicines manufacturing strategy within the KTN where the focus is on supporting the innovation needs of this sector working across biosciences, biotechnology, health, pharmaceuticals and manufacturing, bioprocessing and medicines manufacturing including small molecule drugs, biopharmaceuticals and cell and gene therapies, and the value chain associated with these are of particular focus in the KTN.

 

He is also a steering group member for the Medicines Manufacturing Industry Partnership (MMIP) and has recently led the secretariat function for the Advanced Therapies Manufacturing Taskforce.

 

Mark assists companies build collaborations, raise awareness of funding opportunities and make academic links as appropriate for their business needs. He is also the Programme Coordinator for the Bioprocessing Research Industry Club (BRIC), a BBSRC led research club supported by EPSRC, KTN and member companies.

 

Prior to joining the KTN, he held senior positions in academia and also business working in biomanufacturing, development and consultancy across Biopharmaceuticals, Pharmaceuticals, Industrial Biotechnology and Food and Drink.

Professor Tim Dafforn

Professor of Biotechnology, University of Birmingham and Chief Scientific Advisor, BIS

Tim was appointed as BIS Chief Scientific Adviser in June 2015.  He was entrepreneur in residence at BIS from 2014 - 2015 with a remit to champion activities in synthetic biology in the department and has extensive scientific and entrepreneurship experience.

 

As BIS’s Chief Scientific Adviser in the Strategy Directorate, a part-time role, he has responsibility for providing the best quality independent advice and evidence to Ministers on science, technology, engineering and mathematics (STEM); discussing and facilitating the implementation of policy on STEM; identifying and sharing best practice in STEM-related areas, including the use of scientific-advice in policy making and facilitating communication on high profile STEM-related issues and those posing new challenges and opportunities for government.

 

As Professor of Biotechnology at the University of Birmingham, Tim has established himself as a scientific multi-disciplinarian with more than 100 publications in Biology, Chemistry, Physics and Medicine.


Tim is currently leading a team of 12 scientists to research new methods to detect pathogens and infections and is developing a device that can be used by GPs to diagnose and recommend treatment.  He is particularly interested in commercialising science for the common good.
Tim has worked to develop new national research policies as part of the Biotechnology and Biological Sciences Research Council (BBSRC), new ways of working strategy panel, and the Synthetic Biology Leadership Council. He is head of policy, a trustee and member of the executive at the Biochemical Society.

Professor Paul Dalby

Co-Director, EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies

Paul is Co-Director of the EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies, Director of the associated EPSRC Centre for Doctoral Training, and Chairman of the Royal Society of Chemistry Biotechnology Group Committee. 

 

His research focuses on routes to improve therapeutic proteins for ease of manufacture, formulation and delivery to patients.  His work combines protein engineering and formulation, with biophysical characterisations, to understand the factors that influence protein stability, and to guide protein engineering for improved properties.

Dr Mike Davies

Vice President, Protein Sciences, F-star Biotechnology

Mike has extensive experience in the development and manufacture of recombinant protein therapeutics.  Currently he is VP, Protein Science at F-star Biotechnology, a clinical stage biopharmaceutical company developing novel bispecific antibodies (mAb²) for Immuno-Oncology through the application of its highly efficient Modular Antibody Technology™ platform. Prior to this he was Head of Analytical Strategy at the National Biologics Manufacturing Centre, a UK-based technology innovation centre part of the Centre for Process Innovation & the UK Catapult network. Previously, he worked at Lonza Biologics where he held numerous leadership positions including Head of Analytical Services.

Dr Chris Dowle

Director of Future Business, Centre for Process Innovation

Chris became Director of Future Business focusing on healthcare in January 2016.  This new role will see him develop and implement a Healthcare strategy and business plan for CPI.

 

Chris has worked at CPI as a director since the day it began trading, helping companies test, develop and scale up sustainable processes, products and energy solutions.  His practical and commercial approach enables customers to sustain competitiveness and enter new markets as quickly as possible

 

Following his PhD at the University of Strathclyde in 1988, Chris started his career as a research chemist and developed his technical career across a range of roles from separations technology through to plant operations support and then moved into new disciplines in, engineering and biotechnology.  He has run businesses at CPI and before in global business management and technology licensing

Dr Jim Faulkner

Head of Manufacturing, Autolus

Jim is responsible for process development, manufacturing and supply chain for Autolus, a recently-formed spin-out from University College London (UCL) that is specialising in T-cell immunotherapy using Chimeric Antigen Receptor technology. Autolus is pursuing a number of targets with the aim of improving treatments for both haematological and solid cancers.

Previously, Jim was head of manufacturing and supply for the rare diseases unit at GlaxoSmithKline, where he played an important role in developing their ex vivo gene therapy portfolio for serious rare childhood diseases.

Jim obtained his PhD in molecular biology in association with the University of Kent.  He has a track record of publications and patents in the biopharm field.

Sharon Grimster

General Manager, Wales, ReNeuron

Sharon joined ReNeuron in 2013 and was subsequently appointed as General Manager of the Wales facility in September 2014.   Sharon has significant experience in pharmaceutical development, and she has a particular expertise in ATMP and biologics manufacturing.  

 

Prior to working at ReNeuron, Sharon held senior team roles at F-star and Antisoma, where she was responsible for a range of development functions, including project management, regulatory affairs, manufacturing, quality and general operations.  Sharon started her pharmaceutical career at Celltech, where she led teams in project management, manufacturing and research.

 

Sharon qualified as a coach at the Henley Business School and has a B.Sc. from the University of Leicester and a Diploma in Management Studies.  She is also an active member of several significant industry committees.

Julian Hanak

Vice President, Manufacturing and CMC, NightstaRx

Julian has spent more than 25 years in biologics product development with specific expertise in viral and non-viral gene therapy, antibody and recombinant vaccine products.  He has held numerous manufacturing and commercial senior management positions and recently joined NightstaRx from Cobra Biologics where he served as Commercial Director. 



Prior to that Julian was Senior Vice President of Development at Renovo plc where he was responsible for drug development and outsourcing.  He has also held research and development positions at AstraZeneca, Bio Products Laboratory Ltd and the National Institute for Medical Research. 

Professor Melissa Hanna-Brown

European Head and Analytical Sciences, Global Research and Development, Pfizer

Melissa is European Head and Analytical Sciences at Pfizer Global R+D labs (Sandwich, UK).  She is an expert in the global Technology and Innovation team who use their knowledge to provide a lens on the dynamic external innovation ecosystems that have the potential to impact the Small Molecule Pharmaceutical Sciences development organisation.  They use this knowledge to inform the shaping and delivery of the technology and innovation strategy and vision for the organisation and to facilitate collaborations with external organisations to achieve this strategy. 



In previous roles Melissa has been the Analytical Lead for development programmes prior to regulatory filings and has represented Pfizer in these programmes in front of regulatory agencies including the FDA.  Prior to Pfizer, she was employed in the Department of Pharmacy, Kings College London as Lecturer in Separation Sciences and led a research group.  Melissa is now a Visiting full Professor in the Department of Chemistry at the University of Warwick, a Fellow of the RSC, an elected RSC Council member, the President of the RSC Analytical Division and chair the UK Analytical Chemistry Trust Fund.  She represents Pfizer on the EFPIA Analytical Methods Working Group and also sits on the British Pharmacopoeia Analytical Quality by Design Working Party. 

Hans Johansson

Application Manager, Purolite

Hans is application manager at Purolite R&D, Llantrisant, Wales.  He has spent more than 30 years in the Biotech industry, most of the time in research and development with a special focus on design and application of industrial chromatography resins. He frequently publishes in scientific papers and is the holder of more than ten patents in the area of resin design and large scale protein purification, (including Protein A affinity and multi-modal chromatography resins). He is currently working with development and applications of novel, agarose-based, chromatography resins. 

Alan Johnston

Technical Business Manager, Booth Welsh

Alan is the Technical Business Manager for Booth Welsh Integrated Engineering Services, who provide integrated engineering services in process design, electrical, control and instrumentation design, systems integration and asset management services both in the UK and overseas.  He has held a number of senior engineering, management and business development roles within the Pharmaceutical and Life Sciences sector, his previous role being UK Head of Pharmaceutical and Life Sciences Business for a Multinational product and solutions supplier.   A key part of his current role is engaging with Pharmaceutical and Life Science manufacturers translating business and operational requirements into delivered technical solutions acknowledging current trends, initiatives and regulations driving the sector. 

 

Alan’s career began as an Instrument Artificer apprentice with Imperial Chemicals Industries (ICI), before moving into Process Automation projects and solution delivery within the Chemical, Oil and Gas and Pharmaceutical Industries.  Subsequent roles have taken Alan into sales, key account Management and consultative positions.  He is a holds Chartered Engineering status and is a member of the IET

Dr Peter Levison

Senior Marketing Director - Downstream Processing, Pall Life Sciences

Peter is responsible to the biopharmaceutical business for the global product management of the downstream processing portfolio of products. This embraces sorbent and membrane chromatography media, process chromatography columns and control skids, tangential flow filtration cassettes and systems and continuous processing technologies. He joined Pall in July 2003 but has over 20 years’ experience in the biopharmaceutical industry, holding positions of increasing responsibility in research and development, technical management, and product management.

 

Peter holds a BSc (Hons) Class I in Biochemistry from the University of Manchester, Manchester, UK and a PhD gained in the Department. of Biochemistry, University of Manchester.  He has an MBA awarded through the Open University Business School, Milton Keynes, UK.  He is a member of various professional bodies and has the status of C.Chem, FRSC (Chartered Chemist and Fellow of the Royal Society of Chemistry in the UK) and C.Biol, FRSB (Chartered Biologist and Fellow of the Royal Society of Biology in the UK).

Dr John Liddell

Consultant, JML Biotechnology Consulting

John, prior to establishing JML Biotechnology Consulting, providing consultancy services to the bioprocessing industry, and previously held senior bioprocessing development positions with FUJIFILM  Diosynth Biotechnologies.  There he was responsible for developing and applying innovative solutions for a diverse range of biotherapeutics for the company’s international client base.

 

Before FUJIFILM he held senior bioprocessing development roles in ICI, Zeneca, Avecia and Merck.  He has broadly based experience covering recovery of biopharmaceutical products from both microbial and mammalian cell expression systems.

 

John has been directly involved in all phases of bioprocess development from preclinical and early phase process definition through to late phase process and product characterisation as well as process validation.  He has been responsible for implementation and development of innovative process technologies. 

Professor Michael Linden

Vice President, Gene Therapy, Pfizer

Michael received his PhD in Biochemistry and Molecular Biology at the University of Zürich, Switzerland. He trained in Molecular Virology under the guidance of Prof. Kenneth I. Berns at Cornell University Medical College, N.Y.  After his postdoctoral training, he joined the faculty at Mount Sinai School of Medicine in New York, where he used a multidisciplinary approach to understanding the molecular mechanisms and the potential applicability of site-specific genome integration by adeno-associated virus (AAV).  In 2007, Michael moved continents to set up a new research group at King’s College London.

 

Throughout his career, Michael has engaged in the field of AAV-mediated gene therapy and, more recently, took up the role as the Director of the UCL Gene Therapy Consortium where he is responsible for clinical grade vector production and the support for further developments in UK based gene therapy efforts.  In this context, he is actively engaged in translational projects aimed at the development of novel therapies using AAV-based vectors.

 

Michael joined Pfizer Inc in December 2014 as the VP of Gene Therapy, for a two-year secondment to establish and lead the Genetic Medicine Institute in London.  In December 2015 Michael took on this role permanently.

Ian McCubbin

Senior Vice President, North America, Japan and Global Pharma Supply Manufacturing, GlaxoSmithKline

Ian moved into his latest role as SVP North America, Japan and Global Pharma Supply within the Global Manufacturing and Supply (GMS) division of GlaxoSmithKline plc (GSK) in January 2013.  Ian joined GSK in 2006, his second spell with the company, and has responsibility for GSK’s in-market supply chain and distribution throughout North America and Japan.  This includes overseeing 17 factories and 7,000 employees globally.

 

Ian is a pharmacist and a member of the Royal Pharmaceutical Society GB with 30 years’ experience in the Pharmaceutical industry working for GSK, Merck Generics and IVAX. His core capability is in the field of manufacturing and supply chain leadership in both the generic sector and the branded sector of the industry.

 

He is a founding Board Director of ViiV Healthcare, a global specialist HIV company established by GlaxoSmithKline and Pfizer in 2009 to deliver advances in treatment and care for people living with HIV.  Shionogi joined ViiV Healthcare in 2012.  Ian also sits on GSK’s Charitable Donations Committee, which is responsible for distributing donations to aligned charities.  He is also Chair of the Medicine Manufacturing Industry Partnership (MMIP) that was jointly established by the Association of the British Pharmaceutical Industry (ABPI) and the UK BioIndustry Association (BIA) in September 2013. Ian holds a degree in Pharmacy from Heriot-Watt University, Edinburgh, is married to Barbara, also a pharmacist working in the NHS, and they have two grown up children.

Dr Damian Marshall

Head of Analytical Development, Cell and Gene Therapy Catapult

Damian is the head of analytical development for the Cell and Gene Therapy Catapult and has over 15 years of industrial experience focussed on the development of cell therapies and the implementation of new technologies for product characterisation.  His team works closely with a wide range of cell and gene therapy developers to address some of main analytical challenges faced within the field. These include the application of inferential technologies to support closed manufacture, development of rapid surrogate assays for product release testing and the development of methods to support real time release.

 

Damian has published widely on his work and has authored a number of national and international guidance documents for the cell therapy field.

Dr James Miskin

Chief Technical Officer, Oxford BioMedica

James is Chief Technical Officer at Oxford BioMedica Plc. He obtained his PhD in bacterial molecular biology in 1995 from the University of Leeds, UK. He then worked for over five years as a post‐doctoral research scientist at the UK government‐funded Institute for Animal Health, investigating viral‐host interactions of the haemorrhagic pathogen African Swine Fever Virus.

 

James then joined Oxford BioMedica (OXB) in December 2000 as a specialist in molecular virology. Since that time, he has worked in several research and development areas, in particular developing methods to investigate the safety profile of lentiviral vectors, and is a named inventor on several patents in the field. James has significant experience in GxP assay development, routine testing, manufacturing, manufacturing development and analytical development.

 

In his current role James is a member of the company’s senior executive team (SET) with overall leadership responsibility for two teams within the Company: Manufacturing and Manufacturing Development. The Manufacturing team is responsible for routine GMP production, supply chain and oversight of technical programmes with our strategic partners, including Novartis and Sanofi. The Manufacturing development team is responsible for manufacturing process development, technical support, new process introduction and technology transfer (for internal and partnership manufacturing).

Fergal O’Brien

Director of Biologics, Centre for Process Innovation

Fergal is responsible for Biologics at CPI. He is a Biochemist with over 30 years’ experience in the Biotechnology and Fine Chemical Industry, where he gained extensive experience in successfully managing technical programmes and commercialising novel technologies across the biotechnology sector.

 

In 1982 he joined a research group at the Royal Free Hospital which was the first to purify Factor VIII. Fergal spent the next 25 years in industry with roles in R&D, operations, business development and senior management for companies including Celltech, Enzymatix, Chiroscience, Chirotech, Dow Pharma, Warwick Effect Polymers (as CEO) and Green Biologics.  Fergal joined CPI in 2013 as Head of Operations throughout the build of CPI’s National Biologics Manufacturing Centre, and was appointed as Director of Biologics in January 2016.

 

Fergal has a BSc in Biology from City of London Polytechnic and has previously served on the BBSRC’s Exploiting New Ways of Working Strategy Advisory Panel (ENWW SAP).

Dr David Pollard

Executive Director, BioProcess Technologies and Expression BioProcess Development Merck Research Laboratories, MSD

David is an executive director within Bioprocess Development of the Merck Research Labs (Merck Sharp Dohme).  He has over 20 years’ experience of bioprocess development for the clinical and commercial manufacturing of anti infectives, bioconversions, vaccines and biologics, using a range of expression systems.

 

David’s current assignment is leading a dedicated team to apply next generation technologies to improve the efficiency and lower the costs of the biologics platform.  This encompasses an end to end approach from cell line development to form/fill, applying single use technologies were appropriate.  He is also tasked with co-leading the Single Use Network at Merck, to ease implementation of single use for simpler, faster and lower cost processing.

 

Since completing his PhD in Biochemical engineering at University College London David has written over 20 first author manuscripts covering a diverse range of activities from the first industrial example of fermentation monitoring using in situ Mid IR, to fermentation scale up strategy, bioconversions and high throughput process development.

 

David’s current interests involve innovative process design. This recently included the first example of the automated end to end continuous bioprocessing of CHO mAb at lab scale enabled by single use technology.

Ian Rees

Manager, Inspectorate Strategy and Innovation Unit, MHRA

Ian is the Manager for the Inspectorate Strategy and Innovation Unit. This unit leads the development of the Inspectorate strategy across all GXP disciplines linking Agency and Government priorities to the work of the Group.

Before becoming an inspector, Ian worked for a start-up biopharmaceutical firm for 14 years and is a veterinary surgeon by original qualification. Ian was a GMP inspector with the Veterinary Medicines Directorate for two years prior to joining MHRA in 2001.  In 2004 Ian became an Operations Manager with responsibility for the team of GMP inspectors based in London.  In 2006 he was promoted to his current role. Ian now has a focus on biological/biotechnology products and blood components.  He is the MHRA’s representative on the EMA’s GMP/GDP Inspectors Working Group, this group has as its key responsibility the development and maintenance of GMP and GDP.

Ian was the rapporteur for the 2013 revision of Annex 2 of EU GMP, which gives guidance on the manufacture of human biological medicinal products which includes ATMPs. Ian is also heavily involved in the MHRA's Innovation Office and the UK cross-Agency (HTA, HRA, HFEA and MHRA) Regenerative Medicine Regulatory Advice Service to provide a ‘one stop shop’ (OSS) service for this new sector

Dr Michael L Roberts

Founder and Chief Scientific Officer, Synpromics

Michael studied Biochemistry at the University of Glasgow and completed his PhD at the University of Cambridge, where he employed viral vectors to study plasticity in the peripheral nervous system. He then proceeded to a Post-Doc position at Royal Holloway, University of London, where he worked on developing novel gene therapies for neuromuscular disorders.  In 2002 he moved to Greece on a Marie Curie fellowship to set up a functional genomics facility at the National Hellenic Research Foundation.

 

After spending five years running Gene Therapy R&D activities for a small US Biotech firm, operating out of Athens, called Regulon, he moved back to Edinburgh in 2010 to establish Synpromics where is the company’s Chief Scientific Officer.

Dr Jagjit Singh Srai

Jagjit is Head of the Centre for International Manufacturing, Institute for Manufacturing, University of Cambridge.  His research, funded by national and international funding bodies, focuses on the analysis, design and operation of international production, supply and service networks.  As Research Director of Project Remedies, a £23 million pre-competitive collaborative research programme involving leading Pharmaceutical firms, applied research explores how new technologies may transform future healthcare supply chains.  Jag’s previous roles have been in industry working as a Supply Chain Director of a multinational regional business, Technical Director of a national business and other senior management positions within front-line operations. Jag also advises leading multinationals, governments and international institutions including UNCTAD, UNIDO, WEF.  Dr Srai holds a first-class honours degree in Chemical Process Engineering from Aston University, a PhD in International Supply Networks from Cambridge University, is a Chartered Engineer and a Fellow of the Institute of Chemical Engineers.

Dr Dave Simpson

Chief Executive Officer, Glythera

Dave co-founded Glythera Ltd in April 2012 and relocated the business to the North East whilst refocussing it into an Antibody Drug Conjugate Development Company underpinned by its proprietary, second generation conjugation platforms and more recently, through access to ultra-potent cytotoxic payloads.  Having raised £4.5 million to date through the North-East Technology Fund and IP Group, Glythera is rapidly progressing its assets, including ADCs, through early stage proof of concept studies.

 

Dave started his industrial career, joining Cobra Biologics (now Cobra Biomanufacturing) to develop proprietary, commercially viable expression systems for the production of high value recombinant therapeutics before moving to Eden Biodesign where he headed Process Development.  Here, he had responsibility for molecular biology, cell line/strain development, fermentation/downstream development and Tech Transfer for mammalian, microbial and viral based production systems.  After its acquisition by Watson Pharmaceuticals (now Allergan) in 2010, Dave moved to lead the company’s biosimilar programmes

Professor Adrian Thrasher

Professor of Paediatric Immunology and Wellcome Trust Principal Research Fellow, Great Ormond Street Institute of Child Health, UCL

Adrian is Professor of Paediatric Immunology and Wellcome Trust Principal Research Fellow at the UCL Great Ormond Street Institute of Child Health, and Honorary Consultant Paediatric Immunologist at Great Ormond Street Hospital for Children NHS Foundation Trust.  He is the Programme Head of Infection, Immunity and Inflammation at UCL GOS ICH and has a long-standing research and clinical interest in development and application of gene therapy.  He is Director of the Clinical Gene Therapy Programme, and Theme Leader of the Gene Stem and Cellular Therapies theme of the Biomedical Research Centre, at UCL GOS ICH/GOSH.  Adrian is PI on several clinical trials for immunodeficiency and is Director of the clinical gene therapy GMP facility, managing a team of trial coordinators, clinical scientists, and quality systems personnel.

 

Adrian’s clinical interests are the diagnosis and treatment of patients with primary immunodeficiency.  His specialist interests are in the Wiskott-Aldrich Syndrome (WAS), disorders of innate immunity, and Autoimmune Lymphoproliferative Syndrome.  His team at UCL GOS ICH/GOSH are conducting trials of somatic gene therapy for various forms of PID including SCID-X1, CGD, ADA-SCID, and WAS.  Research interests include the pathophysiology of primary immunodeficiency syndromes especially WAS, the actin cytoskeleton in haematopoietic cells, the development of somatic gene therapy, and thymus transplantation. 

Professor Nigel Titchener-Hooker

Dean of Faculty of Engineering Sciences, UCL

Nigelis Dean of the Faculty of Engineering Sciences at UCL.  Previously he headed the Department of Biochemical Engineering, where he still directs the EPSRC Centre for Innovative Manufacturing of Emerging Macromolecular Therapies and the new EPSRC Manufacturing Hub.  His research interests centre on the delivery of whole bioprocess solutions and in particular the interface between unit operations.

 

Nigel is recognised internationally for his research and has built highly successful collaborations with leading individuals across disciplines. His work has attracted over £45 million of research grant funding which has generated more than £10 million of industrial cash and geared £23 million of in-kind contributions.  He led the Department to win a Queens Anniversary Trust Award for its pioneering studies underpinning the bioprocessing industry in 2013. 

Dr Paul Varley

Vice President, Science and Collaborations and Biopharmaceutical Development (Cambridge) Site Lead, MedImmune

Paul is Vice President, Science and Collaborations, Biopharmaceutical Development at MedImmune, Ltd., Cambridge (formerly Cambridge Antibody Technology, CAT).  Paul joined CAT in 1998 as Director of Pharmaceutical Sciences and was promoted to VP of Biopharmaceutical Development in 2004, a position he held until 2013.  Previously, he was Head of Protein Science at British Biotech from 1993-1998 and had served as a staff scientist at the National Institute of Biological Standards and Control (NIBSC), UK.  He has also undertaken post-doctoral research at the University of Newcastle upon Tyne and at the U.S. National Institutes of Health.  Paul holds a degree in Biomolecular Sciences from Portsmouth Polytechnic and a doctorate from the University of Newcastle upon Tyne.

 

Paul is a member of the Advisory Board of the CPI UK National Centre for Biologics Manufacture and the chair of the University College London EPSRC Centre for Innovative Manufacturing of Emergent Macromolecular Therapies. He has also been involved with many other activities in the Biopharmaceutical/bioprocessing space including the European Biotech Enterprises (EBE) Biomanufacturing Committee; bioprocessUK steering group (ex-chair); the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Biotherapeutics group; the UK BioIndustry Association Manufacturing Advisory Committee and the Bioprocessing Industry Research Club.    

 

Paul is a member of the British Pharmacopeia (BP) Commission, and Vice Chair of BP Expert Advisory Group on biological and biotechnological products.  He is also a member of the EP Expert Committee on Monoclonal Antibodies and a member of BP panel of experts for Blood Products.  

Dr Dirk Voelkel

Chief Technology Officer, Innovation and Analytics Life Science, GE Healthcare Life Sciences

Dirk is Chief Technology Officer, Innovation and Analytics Life Science and joined GE Healthcare Life Sciences in July 2012.  In his role, he manages the R&D and technology portfolio of GE Life Sciences and Life Science innovation activities.  Previously, he headed the Research and Technology department in Roche Diagnostics Diabetes Care Mannheim, developing new technologies to address the needs of diabetic patient’s world-wide.

 

Previously Dirk was a technology scout in the San Francisco bay area and a project leader in R&D, developing systems for glucose monitoring.  Before joining industry, he was a researcher at the Max-Planck-Institut for Fluid Dynamics in Göttingen, Germany and Sandia National Laboratories, Livermore, CA.

 

Dirk received a doctorate and diploma for Physics of the University of Göttingen. He holds eight patents.

Dr Stephen Ward

Chief Operating Officer, Cell and Gene Therapy Catapult

Stephen was appointed Chief Operating Officer of the Cell Therapy Catapult in January 2013.  He brings over 20 years of biological medicine research, development, and manufacturing experience to the organisation.  Stephen enjoys bringing cutting edge technologies to patients, by developing commercially viable products and has developed and validated scaleable, commercial manufacturing processes for cell based medicinal products, vaccines, and recombinant biologicals using Quality by Design principles.

 

Prior to joining the Cell Therapy Catapult, Stephen worked for several biotech and biopharma companies.  He was Development Director at both Onyvax and Stabilitech.  At Stabilitech he led the exploitation of the company’s vaccine and biopharmaceutical stabilisation platform, and expanded it into the cell therapy arena.  At Onyvax he played a key executive role in the Immune oncology programme, and at Medeva he worked on the hepatitis immunotherapy and antigen delivery platform.  



Stephen is passionate about securing and growing the UK manufacturing and development supply chain.  He is the current Chair of the UK BioIndustry Associations (BIA) Manufacturing Advisory Committee, actively promoting and supporting UK bio-manufacturing at Government as well as grass root level.  He, also, sits on various academic Advisory Boards.  His first degree was from the University of Birmingham, specialising in Infection and Immunity, and his second degree from the Medical School of Southampton University developing group B meningococcal vaccine candidates.